| Literature DB >> 34963884 |
Sheena Yurchak1, Amy Rawlinson1, Jessica Schaub1, Yana Ilin Shpilkerman2, Colleen Makarowski1, Kirsten Goddard1, Mohit Bhutani3, Ann-Carol Comeau1.
Abstract
BACKGROUND: Pulmonary rehabilitation (PR) is an evidence-based, nonpharmacological intervention aimed to improve quality of life for patients living with Chronic Obstructive Pulmonary Disease (COPD). Unfortunately, in Canada, most PR programs are hospital based and these are few in number; therefore, accessibility to PR programs is limited.Entities:
Keywords: community care; lung diseases; patient care team; program evaluation; self-management
Year: 2021 PMID: 34963884 PMCID: PMC8698156 DOI: 10.29390/cjrt-2021-040
Source DB: PubMed Journal: Can J Respir Ther ISSN: 1205-9838
Breathing for Health program content
| Week | Content |
|---|---|
| 1 | Healthy lifestyles, goal introductions, pretest |
| 2 | Lung disease pathology, medication and inhaler device review |
| 3 | Stress management, motivational barriers, breathing management strategies |
| 4 | Exercise, nutrition |
| 5 | SMART |
| 6 | Personal directives, enduring power of attorney |
| 7 | Aggravating factors, exacerbation management, action plans |
| 8 | Goal sharing, questions, celebration, post-exercise commitment, post-test |
S, specific; M, measurable; A, achievable; R, realistic; T, timely.
Breathing for health participant demographics
| Demographic | Total ( | Completed program ( | Incomplete or cancelled ( | |
|---|---|---|---|---|
|
| <0.05 | |||
| Male | 107 (51) | 75 (57) | 32 (42) | |
|
| n.s. | |||
| < 60 | 24 (12) | 14 (11) | 10 (13) | |
| 60–79 | 147 (70) | 99 (75) | 48 (62) | |
| 80+ | 38 (18) | 19 (15) | 19 (25) | |
|
| n.s. | |||
| Current smoker | 30 (14) | 19 (14) | 11 (14) | |
| Ex-smoker | 116 (56) | 95 (72) | 21 (27) | |
| Nonsmoker | 15 (7) | 13 (10) | 2 (3) | |
| Missing | 48 (23) | 5 (4) | 43 (56) | |
|
| n.s. | |||
| COPD or Asthma Only | 10 (5) | 9 (7) | 1 (1) | |
| 1 | 28 (13) | 24 (18) | 4 (5) | |
| 2 | 25 (12) | 18 (14) | 7 (9) | |
| 3 | 38 (18) | 26 (20) | 12 (16) | |
| 4 | 30 (14) | 24 (18) | 6 (8) | |
| 5+ | 34 (16) | 30 (23) | 4 (5) | |
| Missing | 44 (21) | 1 (1) | 43 (56) | |
|
| n.s. | |||
| Hypertension | 94 (45) | 71 (54) | 23 (30) | |
| Dyslipidemia, hyperlipidemia, hypercholesterolemia | 73 (35) | 62 (47) | 11 (14) | |
| Gastroesophageal reflux disease | 52 (25) | 40 (30) | 12 (16) | |
| Arthritis | 52 (25) | 38 (29) | 14 (18) | |
| Coronary artery disease | 36 (17) | 29 (22) | 7 (9) | |
| Anxiety | 34 (16) | 27 (21) | 7 (9) | |
| Depression | 33 (16) | 26 (20) | 7 (9) | |
| Hypothyroidism | 29 (14) | 21 (16) | 8 (10) | |
| Sleep apnea | 29 (14) | 26 (20) | 3 (4) | |
| Diabetes | 27 (13) | 21 (16) | 6 (8) | |
| Osteoporosis | 23 (11) | 17 (13) | 6 (8) | |
| Pulmonary fibrosis | 10 (5) | 9 (7) | 1 (1) | |
| Other | 29 (14) | 25 (19) | 4 (5) | |
Includes comorbidities such as: hiatus hernia, transient ischemic attack, diverticulosis, chronic kidney disease, glaucoma, polymyalgia rheumatic, obesity hypoventilation symptom, thyroid disease, and/or bipolar disorder.
Descriptive statistics and significance between pre- and post-program data for 6MWD, Δ30-STST, CAT, SGQL, and EQ-5D (Index and VAS)*
| Assessment Tool |
| Pre-mean (STD) min.–max. | Post-mean (STD) min.–max. |
|
|---|---|---|---|---|
|
| ||||
| At risk (<300 m) at the beginning | 28 | 237 (62) 84–294 | 296 (75) 84–405 | <0.05 |
| Overall | 126 | 374 (102) 84–585 | 435 (115) 84–756 | <0.05 |
|
| ||||
| Less than 8 reps (at risk at the beginning) | 24 | 6.2 (1.0) | 9.3 (2.8) | <0.05 |
| Between 8 to 10 reps (at the beginning) | 54 | 8.9 (0.8) | 11.1 (2.4) | <0.05 |
| More than 11 reps (at the beginning) | 44 | 12.7 (1.9) | 13.6 (3.0) | n.s. |
| Overall | 122 | 9.8 (2.8) 3–20 | 11.6 (3.1) 4–22 | <0.05 |
|
| ||||
| Overall | 105 | 17.4 (6.9) | 15.6 (6.5) | <0.05 |
|
| ||||
| Symptom | 67 | 53.7 (22.2) 0–100 | 52.1 (21.8) 2–91 | n.s. |
| Activity | 67 | 60.3 (22.4) 0–94 | 57.5 (24.5) 0–100 | n.s. |
| Impact | 67 | 30.2 (18.0)0–85 | 29.9 (20.7) 0–87 | n.s. |
| Overall | 67 | 43.2 (17.8) 4.8–84 | 40.6 (18.5) 3–75 | n.s. |
|
| ||||
| EQ-5D Index | 117 | 0.77 (0.17) 0.08–0.95 | 0.8 (0.15) 0.14–0.95 | <0.05 |
| EQ-5D VAS | 117 | 67 (18.3) 30–100 | 70 (16.1) 20–100 | <0.05 |
Note: 6MWD, six minute walk distance; Δ30-STST, 30 second sit to stand test; CAT, COPD assessment test; SGQL, St. George’s respiratory quality of life questionnaire.
Includes only patients that have both pre- and post-measurement.
Frequency and significance between pre- and post-program data for emergency department visits
| 12-month pre- versus post-program |
| Pre-mean (STD) min.–max, | Post- mean (STD) min.–max. |
|
|---|---|---|---|---|
| Completed program | 58 | 1.9 (2.4) | 1.2 (1.5) | <0.05 |
| Incomplete/cancelled | 37 | 1.1 (0.8) | 0.8 (1.2) | n.s. |
| Overall | 95 | 1.6 (2.1) | 1.0 (1.4) | <0.05 |